Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON FORTE versus VESPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON FORTE versus VESPRIN.
ETRAFON-FORTE vs VESPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-FORTE is a combination of perphenazine (a phenothiazine antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system. Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Additionally, amitriptyline blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
Trifluoperazine is a typical antipsychotic that blocks postsynaptic D2 dopamine receptors in the mesolimbic pathway. It also has alpha-adrenergic blocking and anticholinergic effects.
ETRAFON-FORTE (perphenazine 4 mg / amitriptyline 25 mg) oral tablets: 1 tablet three times daily or 1 tablet four times daily. Maximum daily dose: 4 tablets (perphenazine 16 mg / amitriptyline 100 mg).
10-50 mg intramuscularly every 4-6 hours as needed; oral: 25-50 mg every 4-6 hours
None Documented
None Documented
Terminal elimination half-life of perphenazine: 8-12 hours; amitriptyline: 13-36 hours (mean ~20 hours). Steady-state achieved in 3-7 days. Clinical context: twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life ranges from 1 to 2.5 hours, with a mean of approximately 1.5 hours. Due to its short half-life, multiple daily dosing is required to maintain therapeutic levels, and the drug is rapidly cleared after discontinuation.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged). Biliary/fecal elimination accounts for about 15-20% due to enterohepatic recirculation of metabolites.
Primarily hepatic metabolism with metabolites excreted in urine and feces. Approximately 20-30% of a single dose is excreted unchanged in urine, with the remainder as metabolites in urine (30-40%) and feces (20-30%).
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic